Natural Product (NP) Details

General Information of the NP (ID: NP3806)
Name
Ginsenoside compound K
Synonyms
ginsenoside C-K; 39262-14-1; ginsenoside CK; ginsenoside compound K; Ginsenoside K; 20(S)-Ginsenoside C-K; 20(S)-GINSENOSIDE CK; CHEBI:77146; CHEMBL3355096; (2s,3r,4s,5s,6r)-2-[(2s)-2-[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; ginsenoside M1; GM1 saponin; IH901 cpd; Compound-K; ginsenoside-C-K; Sg(S)-ginsenoside c-k; Ginsenoside metabolite M1; (20S)-ginsenoside C-K; 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol; 3-O-Deglucosylginsenoside F2; 20-O-(beta-D-glucopyranosyl)-20(S)-protopanaxadiol; Protopanaxadiol 20-O-glucoside; SCHEMBL18179307; DTXSID60431770; HY-N0904; BDBM50023446; IH 901; MFCD07772261; s9105; ZINC96095535; AKOS037514664; CCG-270260; CS-3840; AB0029014; N1890; X1141; C22127; 262S141; Q-100455; Q27146701; 20-(beta-D-glucopyranosyloxy)dammar-24-ene-3beta,12-diol; 20beta-(beta-D-glucopyranosyloxy)dammar-24-ene-3beta,12beta-diol; (20S)-20-(beta-D-Glucopyranosyloxy)dammara-24-ene-3beta,12beta-diol; (3beta,12beta)-3,12-dihydroxydammar-24-en-20-yl beta-D-glucopyranoside
    Click to Show/Hide
Species Origin Panax ginseng ...     Click to Show/Hide
Panax ginseng
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Apiales
Family: Araliaceae
Genus: Panax
Species: Panax ginseng
Disease Rheumatoid arthritis [ICD-11: FA20] Phase 1 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.956
 
MDCK Permeability
 -5.148
 
PAMPA
 +++
 
HIA
 - - -
 
Distribution
VDss
 -0.436
 
PPB
 84.8%
 
BBB
 ++
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 ++
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 - -
CYP2B6 inhibitor
 +
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 +++
HLM Stability
 +
 
Excretion
CLplasma
 3.355
 
T1/2
 1.968
Toxicity
DILI
 - -
 
Rat Oral Acute Toxicity
 - - -
 
FDAMDD
 - - -
 
Respiratory
 -
 
Human Hepatotoxicity
 +
 
Ototoxicity
 +++
 
Drug-induced Nephrotoxicity
 +++
 
Drug-induced Neurotoxicity
 - - -
 
Hematotoxicity
 +
 
Genotoxicity
 - -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C36H62O8
PubChem CID
9852086
Canonical SMILES
CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)O)C)C)O)C)OC5C(C(C(C(O5)CO)O)O)O)C
InChI
1S/C36H62O8/c1-20(2)10-9-14-36(8,44-31-30(42)29(41)28(40)23(19-37)43-31)21-11-16-35(7)27(21)22(38)18-25-33(5)15-13-26(39)32(3,4)24(33)12-17-34(25,35)6/h10,21-31,37-42H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26-,27-,28+,29-,30+,31-,33-,34+,35+,36-/m0/s1
InChIKey
FVIZARNDLVOMSU-IRFFNABBSA-N
CAS Number
CAS 39262-14-1
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Cisplatin      Bladder cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Down-regulation Expression CDH1  Molecule Info 
Pathway MAP
Down-regulation Expression CDH2  Molecule Info 
Pathway MAP
Down-regulation Expression FN1  Molecule Info 
Pathway MAP
Down-regulation Expression VIM  Molecule Info 
Pathway MAP
                    In-vitro Model MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
                    Experimental
                    Result(s)		 Both CK and DDP can inhibit the proliferation, EMT, and induce the apoptosis in MCF-7 cells, which may be related to the PI3K/Akt pathway. In addition, the combination of CK with DDP can produce a better effect.
          Cytarabine      Mantle cell lymphoma     Click to Show/Hide the Molecular Data of This Drug
                 Augmenting Drug Sensitivity     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Up-regulation Ratio of dCKappa to CDA
                    In-vitro Model HL-60 CVCL_0002 Adult acute myeloid leukemia Homo sapiens
THP-1 CVCL_0006 Childhood acute monocytic leukemia Homo sapiens
U-937 CVCL_0007 Adult acute monocytic leukemia Homo sapiens
NCI-H358 CVCL_1559 Lung adenocarcinoma Homo sapiens
MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
C2C12 CVCL_0188 Healthy Mus musculus
HAECT-1 CVCL_VU17 Healthy Homo sapiens
RAW 264.7 CVCL_0493 Mouse leukemia Mus musculus
MOLM-13 CVCL_2119 Adult acute myeloid leukemia Homo sapiens
                    Experimental
                    Result(s)		 Ara-C combined with CK could achieve the efficacy of higher concentration of ara-C. CK promoted ara-C-induced cell membrane damage and mitochondrial dysfunction and increased ara-C-induced DNA damage.
References
Reference 1 ClinicalTrials.gov (NCT03755258) Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis
Reference 2 Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer. Pharm Biol. 2016;54(4):561-8.
Reference 3 The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells. Biomed Pharmacother. 2020 Dec;132:110812.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link